Granulomatosis with polyangiitis epidemiology and demographics
Granulomatosis with polyangiitis Microchapters |
Differentiating Granulomatosis with polyangiitis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Granulomatosis with polyangiitis epidemiology and demographics On the Web |
American Roentgen Ray Society Images of Granulomatosis with polyangiitis epidemiology and demographics |
FDA on Granulomatosis with polyangiitis epidemiology and demographics |
CDC on Granulomatosis with polyangiitis epidemiology and demographics |
Granulomatosis with polyangiitis epidemiology and demographics in the news |
Blogs on Granulomatosis with polyangiitis epidemiology and demographics |
Directions to Hospitals Treating Granulomatosis with polyangiitis |
Risk calculators and risk factors for Granulomatosis with polyangiitis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2]Associate Editor(s)-in-Chief: Krzysztof Wierzbicki M.D. [3]Cafer Zorkun, M.D., Ph.D. [4]
Overview
The prevalence of Granulomatosis with polyangiitis in Europe ranges from 23.7 to 160 per million person a year, with higher prevalence rates found in northern European countries such as Norway, southern Sweden, northern Germany and the United Kingdom. The incidence of the disease is 2.4 cases per million per year, with higher incidences found in Norway, Sweden, Germany, and the United Kingdom.[1]
Epidemiology
Prevalence
The prevalence of granulomatosis with polyangiitis in Europe ranges from 23.7 to 160 per million persons.[1]
Incidence
The incidence of Granulomatosis with polyangiitis in Europe ranges from 3 to 14.4 per million per year.[1] The incidence of Granulomatosis with polyangiitis in children is around .6 per million per year.[2]
Demographics
The age, sex, and race distribution of Granulomatosis with polyangiitis is dictated by the prevalence of the underlying cause within those demographic groups.
Age
The mean age of diagnosis of granulomatosis with polyangiitis is 58 years. The incidence of the disease in female patients is 70 to 79 years of age and in male patients older than 80 years.[1] The disease most commonly presents in patients that are either middle aged or elderly.[3] [4] [5]
It is rare in children, but has been seen in infants as young as 3 months old.
Race
Granulomatosis with polyangiitis usually affects individuals of the Caucasian race. Other races are less likely to develop Granulomatosis with polyangiitis. [1] [6]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Catanoso M, Macchioni P, Boiardi L, Manenti L, Tumiati B, Cavazza A; et al. (2014). "Epidemiology of granulomatosis with polyangiitis (Wegener's granulomatosis) in Northern Italy: a 15-year population-based study". Semin Arthritis Rheum. 44 (2): 202–7. doi:10.1016/j.semarthrit.2014.05.005. PMID 24932888.
- ↑ Tahghighi F, Moradinejad MH, Aghighi Y, Shiari R, Raeeskarami SR, Salehzadeh F; et al. (2013). "Evaluation of 10-year experience of Wegener's granulomatosis in Iranian children". ISRN Rheumatol. 2013: 694928. doi:10.1155/2013/694928. PMC 3728496. PMID 23956873.
- ↑ Koldingsnes W, Nossent H (2000). "Epidemiology of Wegener's granulomatosis in northern Norway". Arthritis Rheum. 43 (11): 2481–7. doi:10.1002/1529-0131(200011)43:11<2481::AID-ANR15>3.0.CO;2-6. PMID 11083271.
- ↑ Watts RA, Lane SE, Bentham G, Scott DG (2000). "Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom". Arthritis Rheum. 43 (2): 414–9. doi:10.1002/1529-0131(200002)43:2<414::AID-ANR23>3.0.CO;2-0. PMID 10693883.
- ↑ Gonzalez-Gay MA, Garcia-Porrua C, Guerrero J, Rodriguez-Ledo P, Llorca J (2003). "The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions". Arthritis Rheum. 49 (3): 388–93. doi:10.1002/art.11115. PMID 12794795.
- ↑ Mohammad AJ, Jacobsson LT, Mahr AD, Sturfelt G, Segelmark M (2007). "Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden". Rheumatology (Oxford). 46 (8): 1329–37. doi:10.1093/rheumatology/kem107. PMID 17553910.